Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Relevance. Problems of chronic heart failure (HF) after myocardial infarction (MI) prevention of in young and middle-aged men with chronic inflammatory pulmonary diseases (CIPD) remain relevant due to their high prevalence and social significance. Aim. To evaluate changes in the quality of life (QL) indicator associated with heart failure (HF) in men under 60 years old with MI and CIPD to improve prevention and outcomes. Material and methods. The study included men aged 19-60 years old with type I MI. Patients are divided into two age-comparable groups: I - the study group, with CIPD - 166 patients; II - control, without it - 490 patients. A comparative analysis of the QL indicator associated with HF (HFQL) (V. Ironosov) was performed in the selected groups in the first 48 hours (I) and at the end of the third week (II) of MI. The changes and correlations (C. Spearmen) of HFQL with clinical features, metabolic parameters, central and peripheral hemodynamics were studied. Results. HFQL in patients with CIPD was worse than in the control group in both phases of the study (I: 63.6 ± 21.6 and 59.2±20.1; II: 20.7 ± 11.7 and 18.0 ± 12.0, respectively; p˂0.05). Reliable correlations between HFQL and heart rate, blood pressure, parameters of the left ventricle (LV) systolic and diastolic functions, its volume, indicators of the pulmonary circulation, lipid, nitrogen and electrolyte metabolism were revealed. Conclusions. The QL associated with HF is significantly worse in patients with CIPD in the acute and subacute MI periods. The most pronounced negative effect on this indicator in the study group is associated with tachycardia, LV dilatation, its systolic and diastolic dysfunction, pulmonary hypertension, impaired lipid and nitrogen metabolism. The HFQL method is useful as an addition to the complex of examination of patients with MI and MS, starting from the first hours of the disease, for early identification of risk groups for adverse outcomes and the formation of chronic HF.
Relevance. Problems of chronic heart failure (HF) after myocardial infarction (MI) prevention of in young and middle-aged men with chronic inflammatory pulmonary diseases (CIPD) remain relevant due to their high prevalence and social significance. Aim. To evaluate changes in the quality of life (QL) indicator associated with heart failure (HF) in men under 60 years old with MI and CIPD to improve prevention and outcomes. Material and methods. The study included men aged 19-60 years old with type I MI. Patients are divided into two age-comparable groups: I - the study group, with CIPD - 166 patients; II - control, without it - 490 patients. A comparative analysis of the QL indicator associated with HF (HFQL) (V. Ironosov) was performed in the selected groups in the first 48 hours (I) and at the end of the third week (II) of MI. The changes and correlations (C. Spearmen) of HFQL with clinical features, metabolic parameters, central and peripheral hemodynamics were studied. Results. HFQL in patients with CIPD was worse than in the control group in both phases of the study (I: 63.6 ± 21.6 and 59.2±20.1; II: 20.7 ± 11.7 and 18.0 ± 12.0, respectively; p˂0.05). Reliable correlations between HFQL and heart rate, blood pressure, parameters of the left ventricle (LV) systolic and diastolic functions, its volume, indicators of the pulmonary circulation, lipid, nitrogen and electrolyte metabolism were revealed. Conclusions. The QL associated with HF is significantly worse in patients with CIPD in the acute and subacute MI periods. The most pronounced negative effect on this indicator in the study group is associated with tachycardia, LV dilatation, its systolic and diastolic dysfunction, pulmonary hypertension, impaired lipid and nitrogen metabolism. The HFQL method is useful as an addition to the complex of examination of patients with MI and MS, starting from the first hours of the disease, for early identification of risk groups for adverse outcomes and the formation of chronic HF.
Relevance. The lipid metabolism changes during myocardial infarction (MI) in men with metabolic syndrome (MS) may be important for the MI complications development. Aim. To evaluate the lipid metabolism changes in acute and subacute MI periods and their role in the MI complications development in men under 60 years old with MS to improve prevention and outcomes. Material and methods. The study included men aged 19-60 years old with MI and MS. The patients were divided into two age-comparable groups: I - study group, with MS - 95 patients; II - control, without it - 571 patients. A comparative analysis of the lipid metabolism parameters and their dynamics in acute and subacute MI periods in selected groups, analysis of their influence on the risk of MI complications were performed. Results. It was found that in the first hours of MI in the study group, higher levels of triglycerides (3.19 ± 2.34 mmol/l) were noted compared to the control group (2.44 ± 1.75 mmol/l; p=0.02). The dynamics of lipid metabolism at the end of the third week of MI, significant multidirectional changes in all parameters with more pronounced atherogenic changes in the study group were revealed. The risk of MI complications was associated with levels of triglycerides (TG) ˂5.2 (p=0.02), high density (HDL) ≥0.9 (p=0.04) and very low-density lipoproteins (VLDL) ˂0.9 (p=0.04) (mmol/l) of the first hours of MI. Conclusions. The presence of MS impairs lipid metabolism in both acute and the subacute MI periods. In the study group, there is an increase in the levels of atherogenic lipids and their indices during the observation period. MI complications are associated with levels TG ˂5.2; HDL ≥0.9 and VLDL ˂0.9 (mmol/l) during the first hours of MI. It is expedient to use them in predictive modeling.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.